Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS G12D T cell engager
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
KRAS G12D T cell engager is a bispecific T cell engager (TCE) being developed by Myrio Therapeutics for the treatment of KRAS G12D-mutant solid tumors, including lung, pancreatic, and colon cancers. The therapeutic is designed to recognize the KRAS G12D mutation-derived peptide presented by Human Leukocyte Antigen (HLA) on the surface of cancer cells. By simultaneously binding to this peptide-HLA complex and the CD3 epsilon subunit on T cells, the drug facilitates the formation of an immunological synapse, leading to T cell activation and the targeted destruction of tumor cells. It is currently in the discovery stage of development.
- Other names
- KRAS (G12D) T Cell EngagerKRAS G12D T-cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA-A*11
Beyond the preview
Go deeper on KRAS G12D T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12D T cell engager.